FDA accepteert aanvraag voor Gazyva als behandeling van meest voorkomende lupusvorm

The US Food and Drug Administration has accepted an application from Genentech to use Gazyva as a treatment for lupus. Gazyva would target the most common form of the autoimmune disease. The acceptance marks a step forward in the regulatory review process for Roche subsidiary Genentech.